Deep dives
Articles that go further than a reference entry: mechanism, trial design, what the data support and what it does not.
Retatrutide, the peptide the internet calls GLP-3
Why a triple agonist picked up a nickname that does not describe a real hormone — and what its trial data actually show.
28 Aug 2026 · 9 MIN READ
EVIDENCE CHECKBPC-157: separating the claims from the evidence
The most discussed repair peptide on the internet has an enormous animal literature and almost no human trials. Here is the honest state of play.
14 Aug 2026 · 8 MIN READ
COMPARISONGH secretagogues compared: sermorelin, ipamorelin, CJC-1295, tesamorelin
Four peptides that all raise growth hormone, by three different mechanisms, with wildly different levels of evidence.
30 Jul 2026 · 10 MIN READ
PRIMERWhy most peptides have to be injected
Absorption, not chemistry, is what keeps peptides out of pill form — and what a few programmes have done about it.
11 Jul 2026 · 6 MIN READ
METHODHow to read a peptide study without fooling yourself
Five questions that separate a meaningful result from an impressive-sounding one.
25 Jun 2026 · 7 MIN READ
EVIDENCE CHECKMuscle loss on incretin therapy: what the data say
Lean-mass loss is the most cited criticism of GLP-1 drugs. The numbers are more nuanced than either side claims.
05 Jun 2026 · 8 MIN READ